Celularity, headquartered in Florham Park, NJ, is a clinical-stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified natural killer (NK) cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Location: United States, New Jersey, Florham Park
Employees: 201-500
Phone: +1 908-768-2170
Total raised: $250M
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | Section 32 | section32.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.02.2018 | - | $250M | - |
Mentions in press and media 18
| Date | Title | Description |
| 25.07.2025 | BioCellgraft advances strategic commercialization planning for OraFyl™ with its partner Celularity, Inc. | ORAFYL. Oral Health is Overall Health BioCellgraft's recent successful collection of patient cases using OraFyl in dozens of gum and bone related dental procedures positions the product to dominate. The Mouth is the Mirror of the Body, Reve... |
| 07.11.2024 | Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million | Celularity Raises Full Year 2024 Expected Net Sales Guidance to $54 Million to $60 Million, Compared to Previous Guidance of $50 Million to $56 Million October Expected Net Sales of $8.3 Million to $8.9 Million Marks the Highest Single-Mont... |
| 12.03.2024 | Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress | - |
| 07.03.2024 | Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells | - |
| 25.01.2024 | Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions | - |
| 27.07.2023 | Celularity Inc. Announces $3 Million Registered Direct Offering | - |
| 23.05.2023 | Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement For Celularity’s Halal-Certified Biomaterial Products | - |
| 23.05.2023 | Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement For Celularity’s Halal-Certified Biomaterial Products | Builds on Celularity’s December 2022 announcement of Halal Certification of its commercial-stage biomaterial products, and clinical and investigational stage cellular therapeutic programs Marks an important first step in Celularity’s expans... |
| 05.04.2023 | Celularity Inc. Announces $6 Million Registered Direct Offering | - |
| 11.01.2023 | Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East | CH Trading Group will serve as exclusive territories distributor in 100-plus countries with US $225 million minimum purchase commitment Relationship opens access to Celularity's Halal-Certified regenerative biomaterial, health and wellness ... |
Show more